<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02272842</url>
  </required_header>
  <id_info>
    <org_study_id>808734</org_study_id>
    <secondary_id>U1111-1161-5187</secondary_id>
    <nct_id>NCT02272842</nct_id>
  </id_info>
  <brief_title>Vitamin B12, Neurodevelopment and Growth in Nepal</brief_title>
  <acronym>BeLive</acronym>
  <official_title>The Effect of Vitamin B12 Supplementation in Nepali Infants on Growth and Development</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre For International Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tribhuvan University, Nepal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NORCE Norwegian Research Centre AS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre For International Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Globally, vitamin B12 deficiency is one of the most common micronutrient&#xD;
      deficiencies. The only relevant source of Vitamin B12 is animal-source foods. Vitamin B12 is&#xD;
      crucial for normal cell division and is necessary for brain growth as well as for the&#xD;
      maintenance of its normal function. Deficiency is also associated with impaired growth. In a&#xD;
      previous study, we demonstrated that vitamin B12 administration over a period of six months&#xD;
      enhanced growth, and scores on a neuro-developmental test in young Indian children. However,&#xD;
      the overall effect was small and, for the developmental scores significant only in those that&#xD;
      were malnourished at the start of the study.&#xD;
&#xD;
      Our findings need to be verified in trials targeting younger, malnourished children and with&#xD;
      longer supplementation time.&#xD;
&#xD;
      Hypothesis: This proposed study will test three hypotheses; to measure to what extent 2&#xD;
      recommended daily allowances (RDA) of vitamin B12 administration for one year to stunted&#xD;
      children improves; 1) growth, 2) neurodevelopment, and 3) hemoglobin concentration.&#xD;
&#xD;
      Study design: Randomized placebo-controlled trial. Half of the children will receive a paste&#xD;
      containing vitamin B12, the other half the same paste but without vitamin B12.&#xD;
&#xD;
      Study participants and site: 600 malnourished infants in Bhaktapur municipality in Nepal. In&#xD;
      this population we have demonstrated that vitamin B12 deficiency and poor growth is common in&#xD;
      early childhood.&#xD;
&#xD;
      Intervention: Daily administration of a paste containing vitamin B12 or placebo for 12 months&#xD;
&#xD;
      Data: The main outcomes of this study are scores on developmental assessments tools and&#xD;
      growth measured every month for 12 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Scientific basis: Globally, vitamin B12 deficiency is one of the most common micronutrient&#xD;
      deficiencies. The only relevant source of vitamin B12 is animal-source foods. Vitamin B12 is&#xD;
      crucial for normal cell division and differentiation and is necessary for the development and&#xD;
      initial myelination of the central nervous system as well as for the maintenance of its&#xD;
      normal function. Deficiency is also associated with impaired infant and child growth.&#xD;
&#xD;
      In a previous clinical trial, we demonstrated that vitamin B12 administration over a period&#xD;
      of six months enhanced growth and neurodevelopment in young Indian children. The overall&#xD;
      effect on growth was significant but small. We saw an effect on both ponderal (weight for age&#xD;
      z scores) and linear (height for age z scores) growth. However, the overall effects were&#xD;
      driven by the effects in the subgroups of children who were wasted, underweight or stunted at&#xD;
      baseline, and no effect in the children who were not malnourished at baseline. This effect&#xD;
      modification was significant for all three (stunting, wasting, and underweight) baseline&#xD;
      variables. Similarly, the effect of the intervention on neurodevelopmental scores was also&#xD;
      strongest in the subgroup of children that were stunted.&#xD;
&#xD;
      We have for the last 15 years undertaken studies on dietary intake and status in women and&#xD;
      children in Bhaktapur, Nepal. In this site, vitamin B12 deficiency is very common. The&#xD;
      objective of the proposed study is to measure to what extent administration of 2 RDA of&#xD;
      vitamin B12 to stunted children from the last half of infancy and for 12 months affect&#xD;
      neurodevelopment, growth and hemoglobin concentration.&#xD;
&#xD;
      Hypothesis: Daily supplementation of 2 RDA of vitamin B12 in young Nepali children for 12&#xD;
      months improves neurodevelopment, growth and hemoglobin concentration.&#xD;
&#xD;
      Study design: Individually randomized placebo controlled, double blind trial. Children will&#xD;
      be identified in the community and stunted children will be randomized to daily receive a&#xD;
      paste containing vitamin B12 or a placebo paste. The paste will be delivered by trained field&#xD;
      workers every day and by the caregivers on Saturdays and public holidays.&#xD;
&#xD;
      Study participants and site: 600 stunted children aged 6 to 11 months in Bhaktapur&#xD;
      municipality and surrounding areas.&#xD;
&#xD;
      Intervention: Daily administration of a paste containing vitamin B12 or placebo for 12&#xD;
      months.&#xD;
&#xD;
      Comparator: Placebo, identical to the vitamin B12 supplements.&#xD;
&#xD;
      Data: Primary outcomes: (i) neurodevelopmental scores measured by Bayley Scales of Infant and&#xD;
      Toddler Development 3rd edition and the Ages and Stages Questionnaire 3rd edition after 6 and&#xD;
      12 months of supplementation (ii) growth measured by change in height for age, weight for age&#xD;
      and weight for height z-score from study start to end study and growth velocity z scores&#xD;
      during the six first and six last months of supplementation (iii) hemoglobin concentration&#xD;
      after 12 months of supplementation. Secondary: (i) cognitive development in children measured&#xD;
      approximately 3 and 6 years after enrollment, (ii) linear and ponderal growth measured 2 and&#xD;
      3 years after enrollment, (iii) hemoglobin concentration measured 2 and 3 years after&#xD;
      enrollment. All secondary outcomes require additional funding.&#xD;
&#xD;
      Relevance for programs and public health: Improved learning ability and growth in young&#xD;
      malnourished children. If the supplementation is effective this will have consequences for&#xD;
      dietary recommendation to malnourished children worldwide. In contrast to most other relevant&#xD;
      nutritional interventions, vitamin B12 is inexpensive and our body has the ability to store&#xD;
      vitamin B12, up to years. Thus, improving the status of this nutrient for a limited time&#xD;
      period may have impact on learning and productivity beyond the time of administration and&#xD;
      help to lift poor children out of the vicious cycle of poverty and malnutrition.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 20, 2015</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Actual">February 28, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Bayley Scales of Infant Development Version 3</measure>
    <time_frame>12 months</time_frame>
    <description>Cognitive, Fine Motor, Gross Motor, Receptive language, and Expressive language scaled scores of the Bayley Scales of Infant Development version 3. This scale measures different aspects of neurodevelopment. The mean (SD) scores are usually 100 (15), 95% of the population have scores between 70 and 130 (theoretical max/means 0/200). The higher scores, the better neurodevelopment, the scale is normalized on age.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemoglobin Concentration</measure>
    <time_frame>12 months</time_frame>
    <description>Change in hemoglobin concentration from baseline to end study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Growth Velocity Over the First Six Months of Supplementation</measure>
    <time_frame>12 months</time_frame>
    <description>length and weight growth velocity z scores during supplementation z-scores, growth velocity. theoretical values -10 to 10 The higher the value, the faster the growth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictors for Neurodevelopment in Young Nepali Children</measure>
    <time_frame>12 months</time_frame>
    <description>Using the collected data, identify morbidity, stimulation, nutrition, socioeconomic related predictors for neurodevelopment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identify Subgroups of Children Who Benefit From Vitamin B12 Supplementation</measure>
    <time_frame>12 months</time_frame>
    <description>Based on selected baseline variables we will identify subgroups who benefit from vitamin B12 supplementation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Effect of Vitamin B12 Supplementation on Markers of Vitamin B Status</measure>
    <time_frame>12 months</time_frame>
    <description>We will draw a blood sample at study start and at end study to measure to what extent vitamin status is altered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurodevelopment Measured by Other Tools.</measure>
    <time_frame>12 months</time_frame>
    <description>We will measure to what extent vitamin B12 supplementation improves neurodevelopment measured by other tools such as the Ages and Stages Questionnaire (version 3) and the NEPSY II test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immediate Adverse Effects of the Intervention</measure>
    <time_frame>12 months</time_frame>
    <description>We will investigate side effects such as pain, nausea, vomiting, regurgitation, allergic reactions and others after each dose of the intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leucocyte Telomere Length</measure>
    <time_frame>12 months</time_frame>
    <description>Relative leucocyte telomere length at end of the study period. Estimated by real-time PCR analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Duration</measure>
    <time_frame>12 months</time_frame>
    <description>Using actigraph and a structured questionaire on all children at baseline and at end of study measure the extent to which the intervention affects sleep.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Extended Followup: Neurodevelopment</measure>
    <time_frame>3 years</time_frame>
    <description>We will follow the cohort beyond the planned (and funded) project period and measure neurodevelopment using appropriate tests such as the Wechsler tests</description>
  </other_outcome>
  <other_outcome>
    <measure>Surrogate Markers for Neurodevelopment</measure>
    <time_frame>2 years</time_frame>
    <description>If funding allows, measure other markers related to neurodevelopment such as Brain Derived Neurotrophic Factor</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">600</enrollment>
  <condition>Development</condition>
  <condition>Vitamin Deficiency</condition>
  <condition>Malnutrition</condition>
  <arm_group>
    <arm_group_label>Vitamin B12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A paste containing vitamin B12 2µg per 10 mL administered every day. The paste also contains 1 RDA of several other vitamins. The paste is produced by Compact (Norway / India)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A paste containing no vitamin administered every day. The paste also contains 1 RDA of several vitamins, but no vitamin B12. The paste is produced by Compact (Norway / India)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin B12</intervention_name>
    <description>Vitamin B12 in a multivitamin paste.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Vitamin B12</arm_group_label>
    <other_name>Cobalamin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 6 to 11 months&#xD;
&#xD;
          -  Stunted&#xD;
&#xD;
          -  Availability of informed verbal consent&#xD;
&#xD;
          -  Plan to reside in the area for the next 12 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe systemic illness requiring hospitalization&#xD;
&#xD;
          -  Severe malnutrition, i.e. weight for height &lt; -3 z of the WHO standard for this age&#xD;
             group. For ethical reasons these children require micronutrient supplementation and&#xD;
             adequate medical care.&#xD;
&#xD;
          -  Lack of consent&#xD;
&#xD;
          -  Taking B vitamin supplements that include vitamin B12.&#xD;
&#xD;
          -  Severe anemia (Hb &lt; 7 g/dL). This would be a temporary exclusion and the children will&#xD;
             be enrolled if they are successfully treated.&#xD;
&#xD;
          -  Ongoing acute infection with fever or infection that requires medical treatment. This&#xD;
             would be a temporary exclusion and the children will be enrolled after recovery.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>11 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prakash S Shrestha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tribhuvan University, Nepal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tor A Strand, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Innlandet Hospital Trust / University of Bergen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Siddhi Memorial Hospital (SMH),Bhelukhel, Bhimsensthan</name>
      <address>
        <city>Bhaktapur</city>
        <zip>P.O.Box 40</zip>
        <country>Nepal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Nepal</country>
  </location_countries>
  <link>
    <url>https://www.thrasherresearch.org/SitePages/current-grants-all.aspx</url>
    <description>Link to the founding source.</description>
  </link>
  <reference>
    <citation>Taneja S, Strand TA, Kumar T, Mahesh M, Mohan S, Manger MS, Refsum H, Yajnik CS, Bhandari N. Folic acid and vitamin B-12 supplementation and common infections in 6-30-mo-old children in India: a randomized placebo-controlled trial. Am J Clin Nutr. 2013 Sep;98(3):731-7. doi: 10.3945/ajcn.113.059592. Epub 2013 Jul 31.</citation>
    <PMID>23902779</PMID>
  </reference>
  <reference>
    <citation>Strand TA, Taneja S, Ueland PM, Refsum H, Bahl R, Schneede J, Sommerfelt H, Bhandari N. Cobalamin and folate status predicts mental development scores in North Indian children 12-18 mo of age. Am J Clin Nutr. 2013 Feb;97(2):310-7. doi: 10.3945/ajcn.111.032268. Epub 2013 Jan 2.</citation>
    <PMID>23283502</PMID>
  </reference>
  <reference>
    <citation>Black MM. Effects of vitamin B12 and folate deficiency on brain development in children. Food Nutr Bull. 2008 Jun;29(2 Suppl):S126-31. Review.</citation>
    <PMID>18709887</PMID>
  </reference>
  <reference>
    <citation>Black MM. Micronutrient deficiencies and cognitive functioning. J Nutr. 2003 Nov;133(11 Suppl 2):3927S-3931S. doi: 10.1093/jn/133.11.3927S. Review.</citation>
    <PMID>14672291</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 21, 2014</study_first_submitted>
  <study_first_submitted_qc>October 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2014</study_first_posted>
  <results_first_submitted>July 18, 2018</results_first_submitted>
  <results_first_submitted_qc>May 3, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 25, 2021</results_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nepal</keyword>
  <keyword>Cobalamin</keyword>
  <keyword>Neurodevelopment</keyword>
  <keyword>Stunting</keyword>
  <keyword>Growth</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malnutrition</mesh_term>
    <mesh_term>Avitaminosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin B 12</mesh_term>
    <mesh_term>Hydroxocobalamin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data available on request. In order to meet ethical requirements for the use of confidential patient data, requests must be approved by the Nepal Health Research Council (NHRC) and the Regional Committee for Medical and Health Research Ethics in Norway. Requests for data should be sent to the authors, by contacting NHRC (http://nhrc.gov.np), or by contacting the Department of Global Health and Primary Care at the University of Bergen (post@igs.uib.no).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Upon publication of the main outcomes.</ipd_time_frame>
    <ipd_access_criteria>The protocols and the plan of analyses will be available with the main publication. IPD will be available following an application process which involves the ethical committees in Norway and Nepal</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 2, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT02272842/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 15, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT02272842/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The enrollment commenced in April 2015 and ended in February 2017. All children were supplemented daily for one year. Follow-up ended in February 2018</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Vitamin B12</title>
          <description>A paste containing vitamin B12 2µg per 10 mL administered every day. The paste also contains 1 RDA of several other vitamins. The paste is produced by Compact (Norway / India)&#xD;
Vitamin B12: Vitamin B12 in a multivitamin paste.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>A paste containing no vitamin B12 administered every day. The paste also contains 1 RDA of several vitamins, but no vitamin B12. The paste is produced by Compact (Norway / India)&#xD;
Placebo B12: Placebo B12 in a multivitamin paste.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="300"/>
                <participants group_id="P2" count="300"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="284"/>
                <participants group_id="P2" count="290"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vitamin B12</title>
          <description>A paste containing vitamin B12 2µg per 10 mL administered every day. The paste also contains 1 RDA of several other vitamins. The paste is produced by Compact (Norway / India)&#xD;
Vitamin B12: Vitamin B12 in a multivitamin paste.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>A paste containing no vitamin B12 administered every day. The paste also contains 1 RDA of several vitamins, but no vitamin B12. The paste is produced by Compact (Norway / India)&#xD;
Placebo B12: Placebo B12 in a multivitamin paste.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="300"/>
            <count group_id="B2" value="300"/>
            <count group_id="B3" value="600"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.0" spread="1.8"/>
                    <measurement group_id="B2" value="8.1" spread="1.8"/>
                    <measurement group_id="B3" value="8.0" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                    <measurement group_id="B2" value="142"/>
                    <measurement group_id="B3" value="291"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                    <measurement group_id="B2" value="158"/>
                    <measurement group_id="B3" value="309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Nepalese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="300"/>
                    <measurement group_id="B2" value="300"/>
                    <measurement group_id="B3" value="600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Length (cm)</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.837" spread="3.0"/>
                    <measurement group_id="B2" value="65.94" spread="2.9"/>
                    <measurement group_id="B3" value="65.9" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight (kg)</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.3" spread="0.92"/>
                    <measurement group_id="B2" value="7.3" spread="0.92"/>
                    <measurement group_id="B3" value="7.3" spread=".92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Bayley Scales of Infant Development Version 3</title>
        <description>Cognitive, Fine Motor, Gross Motor, Receptive language, and Expressive language scaled scores of the Bayley Scales of Infant Development version 3. This scale measures different aspects of neurodevelopment. The mean (SD) scores are usually 100 (15), 95% of the population have scores between 70 and 130 (theoretical max/means 0/200). The higher scores, the better neurodevelopment, the scale is normalized on age.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin B12</title>
            <description>A paste containing vitamin B12 2µg per 10 mL administered every day. The paste also contains 1 RDA of several other vitamins. The paste is produced by Compact (Norway / India)&#xD;
Vitamin B12: Vitamin B12 in a multivitamin paste.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A paste containing no vitamin B12 administered every day. The paste also contains 1 RDA of several vitamins, but no vitamin B12. The paste is produced by Compact (Norway / India)&#xD;
Placebo B12: Placebo B12 in a multivitamin paste.</description>
          </group>
        </group_list>
        <measure>
          <title>The Bayley Scales of Infant Development Version 3</title>
          <description>Cognitive, Fine Motor, Gross Motor, Receptive language, and Expressive language scaled scores of the Bayley Scales of Infant Development version 3. This scale measures different aspects of neurodevelopment. The mean (SD) scores are usually 100 (15), 95% of the population have scores between 70 and 130 (theoretical max/means 0/200). The higher scores, the better neurodevelopment, the scale is normalized on age.</description>
          <units>Scaled Scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="289"/>
                <count group_id="O2" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cognitive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="1.6"/>
                    <measurement group_id="O2" value="8.2" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Receptive language</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" spread="2.3"/>
                    <measurement group_id="O2" value="8.9" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Expressive language</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" spread="2.6"/>
                    <measurement group_id="O2" value="8.5" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fine Motor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" spread="1.6"/>
                    <measurement group_id="O2" value="10.9" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gross Motor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" spread="2.0"/>
                    <measurement group_id="O2" value="9.1" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The study had 80% power to detect a standardized effect size of 0.22 and had 90% power to detect an effect size of 0.28. In these calculations, we assumed a loss to follow-up of 10%. Details on the samples size calculations are also presented in the previously published protocol paper.</non_inferiority_desc>
            <p_value>&gt;.16</p_value>
            <p_value_desc>The main analysis was the change in cognitive scores from baseline until the end of the intervention.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.16</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>.35</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-.54</ci_lower_limit>
            <ci_upper_limit>.87</ci_upper_limit>
            <estimate_desc>This is the P-value for the effect on the cognitive scores.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hemoglobin Concentration</title>
        <description>Change in hemoglobin concentration from baseline to end study.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin B12</title>
            <description>A paste containing vitamin B12 2µg per 10 mL administered every day. The paste also contains 1 RDA of several other vitamins. The paste is produced by Compact (Norway / India)&#xD;
Vitamin B12: Vitamin B12 in a multivitamin paste.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A paste containing no vitamin B12 administered every day. The paste also contains 1 RDA of several vitamins, but no vitamin B12. The paste is produced by Compact (Norway / India)&#xD;
Placebo B12: Placebo B12 in a multivitamin paste.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin Concentration</title>
          <description>Change in hemoglobin concentration from baseline to end study.</description>
          <units>g/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="288"/>
                <count group_id="O2" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="1.1"/>
                    <measurement group_id="O2" value="1.0" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Growth Velocity Over the First Six Months of Supplementation</title>
        <description>length and weight growth velocity z scores during supplementation z-scores, growth velocity. theoretical values -10 to 10 The higher the value, the faster the growth.</description>
        <time_frame>12 months</time_frame>
        <posting_date>01/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Predictors for Neurodevelopment in Young Nepali Children</title>
        <description>Using the collected data, identify morbidity, stimulation, nutrition, socioeconomic related predictors for neurodevelopment.</description>
        <time_frame>12 months</time_frame>
        <posting_date>01/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Identify Subgroups of Children Who Benefit From Vitamin B12 Supplementation</title>
        <description>Based on selected baseline variables we will identify subgroups who benefit from vitamin B12 supplementation</description>
        <time_frame>12 months</time_frame>
        <posting_date>01/2025</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Effect of Vitamin B12 Supplementation on Markers of Vitamin B Status</title>
        <description>We will draw a blood sample at study start and at end study to measure to what extent vitamin status is altered.</description>
        <time_frame>12 months</time_frame>
        <population>Comparing mean plasma concentration of cobalamin between the study groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin B12</title>
            <description>A paste containing vitamin B12 2µg per 10 mL administered every day. The paste also contains 1 RDA of several other vitamins. The paste is produced by Compact (Norway / India)&#xD;
Vitamin B12: Vitamin B12 in a multivitamin paste.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A paste containing no vitamin administered every day. The paste also contains 1 RDA of several vitamins, but no vitamin B12. The paste is produced by Compact (Norway / India)&#xD;
Vitamin B12: Vitamin B12 in a multivitamin paste.</description>
          </group>
        </group_list>
        <measure>
          <title>The Effect of Vitamin B12 Supplementation on Markers of Vitamin B Status</title>
          <description>We will draw a blood sample at study start and at end study to measure to what extent vitamin status is altered.</description>
          <population>Comparing mean plasma concentration of cobalamin between the study groups.</population>
          <units>mol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="277"/>
                <count group_id="O2" value="286"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cobalamin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="316.3" spread="1.7"/>
                    <measurement group_id="O2" value="290.1" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>homocysteine'</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="1.3"/>
                    <measurement group_id="O2" value="8.2" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Methyl Malonic acid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="1.9"/>
                    <measurement group_id="O2" value=".4" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurodevelopment Measured by Other Tools.</title>
        <description>We will measure to what extent vitamin B12 supplementation improves neurodevelopment measured by other tools such as the Ages and Stages Questionnaire (version 3) and the NEPSY II test.</description>
        <time_frame>12 months</time_frame>
        <posting_date>01/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immediate Adverse Effects of the Intervention</title>
        <description>We will investigate side effects such as pain, nausea, vomiting, regurgitation, allergic reactions and others after each dose of the intervention.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin B12</title>
            <description>A paste containing vitamin B12 2µg per 10 mL administered every day. The paste also contains 1 RDA of several other vitamins. The paste is produced by Compact (Norway / India)&#xD;
Vitamin B12: Vitamin B12 in a multivitamin paste.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A paste containing no vitamin B12 administered every day. The paste also contains 1 RDA of several vitamins, but no vitamin B12. The paste is produced by Compact (Norway / India)&#xD;
Placebo B12: Placebo B12 in a multivitamin paste.</description>
          </group>
        </group_list>
        <measure>
          <title>Immediate Adverse Effects of the Intervention</title>
          <description>We will investigate side effects such as pain, nausea, vomiting, regurgitation, allergic reactions and others after each dose of the intervention.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Urinary tract infections</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Lower respiratory infections</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Seizure related illness</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Constipation</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other (surgical, diarrhea, sepsis, etc.)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Leucocyte Telomere Length</title>
        <description>Relative leucocyte telomere length at end of the study period. Estimated by real-time PCR analysis</description>
        <time_frame>12 months</time_frame>
        <posting_date>01/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Duration</title>
        <description>Using actigraph and a structured questionaire on all children at baseline and at end of study measure the extent to which the intervention affects sleep.</description>
        <time_frame>12 months</time_frame>
        <posting_date>02/2023</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Extended Followup: Neurodevelopment</title>
        <description>We will follow the cohort beyond the planned (and funded) project period and measure neurodevelopment using appropriate tests such as the Wechsler tests</description>
        <time_frame>3 years</time_frame>
        <posting_date>01/2022</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Surrogate Markers for Neurodevelopment</title>
        <description>If funding allows, measure other markers related to neurodevelopment such as Brain Derived Neurotrophic Factor</description>
        <time_frame>2 years</time_frame>
        <posting_date>01/2023</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Vitamin B12</title>
          <description>A paste containing vitamin B12 2µg per 10 mL administered every day. The paste also contains 1 RDA of several other vitamins. The paste is produced by Compact (Norway / India)&#xD;
Vitamin B12: Vitamin B12 in a multivitamin paste.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>A paste containing no vitamin B12 administered every day. The paste also contains 1 RDA of several vitamins, but no vitamin B12. The paste is produced by Compact (Norway / India)&#xD;
Placebo B12: Placebo B12 in a multivitamin paste.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <description>admitted with diagnosis of abscess over left lateral neck (staph aureus isolated) treated : inj flucloxacillin and inj cefotaxime</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Burn</sub_title>
                <description>The child was burn with hot water on face and head admitted to a tertiary hosptial</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Regurgitation following paste administration.</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="141" subjects_affected="70" subjects_at_risk="300"/>
                <counts group_id="E2" events="134" subjects_affected="63" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile seizures</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="300"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Lower respiratory infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="300"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tor Strand</name_or_title>
      <organization>Innlandet Hospital Trust</organization>
      <phone>+4790971086</phone>
      <email>tors@me.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

